Fuerth, Germany

Stefan Heitner



Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Stefan Heitner in Dronabinol Preparation

Introduction

Stefan Heitner is a notable inventor based in Fuerth, Germany. He has made significant contributions to the field of cannabinoid research, particularly in the preparation of dronabinol. His innovative methods have the potential to impact various applications in the pharmaceutical industry.

Latest Patents

Stefan Heitner holds a patent for a method for the preparation of dronabinol. This invention relates to the cyclization of cannabidiol (CBD) to produce Δ9-tetrahydrocannabinol (Δ9-THC). The method is characterized by the use of an organic solvent and a molecular sieve, which enhances the catalytic properties of the reaction. This innovative approach results in a higher yield of Δ9-THC compared to traditional methods that rely solely on Lewis acid catalysts. Heitner's patent represents a significant advancement in cannabinoid synthesis.

Career Highlights

Stefan Heitner is associated with Bionorica AG, a company known for its research and development in herbal medicine. His work at Bionorica AG has allowed him to focus on innovative methods that can lead to more efficient production processes in the pharmaceutical sector. His dedication to research and development has positioned him as a key figure in cannabinoid innovation.

Collaborations

Stefan Heitner has collaborated with Joachim Erler, contributing to the advancement of cannabinoid research. Their partnership has fostered a productive environment for innovation and development in the field.

Conclusion

Stefan Heitner's contributions to the preparation of dronabinol highlight his innovative spirit and dedication to advancing cannabinoid research. His patent represents a significant step forward in the synthesis of cannabinoids, showcasing the potential for improved pharmaceutical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…